ArticleGut pathogens2026
Clinical and microbial correlates of response to lifestyle intervention in pediatric metabolic dysfunction-associated steatotic liver disease.
Article in Gut pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07731360 (A Non-Invasive Diagnostic Panel for MASLD in Children With Obesity), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Non-Invasive Diagnostic Panel for MASLD in Children With Obesity: Evaluation of a Multiparametric Biomarker Panel and Genetic Risk Score Using LASSO-Regularized Logistic Regression - The PedMASLD-MultiOmics Pilot Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundLifestyle modifications are fundamental in managing metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to evaluate the effects of a 12-week lifestyle intervention on hepatic steatosis, liver function, and gut microbiota composition in pediatric MASLD patients, and to explore clinical and baseline microbial features associated with treatment response.
resultsA total of 40 patients were recruited, and 31 were included after applying exclusion criteria. After 12 weeks, significant reductions were observed in body weight, waist circumference, liver enzymes, and triglycerides. MRI-measured hepatic steatosis decreased from 27.1% to 20.8% (p < 0.05). Greater reductions in hepatic fat were associated with higher daily step counts and a higher proportion of dietary protein intake. Baseline gut microbial composition differed between clinical responder groups. Clostridium sensu stricto 1 was enriched in participants with significant weight loss, Faecalibacterium in those with ALT or GGT improvement, and Lachnospiraceae_ND3007_group in those with MRI-PDFF reduction, with baseline microbial profiles discriminating responders with AUC ≥ 0.75.
conclusionsA 12-week lifestyle intervention led to significant improvements in hepatic steatosis, metabolic parameters, and anthropometric measures in pediatric MASLD. Baseline gut microbial profiles differed between individuals with metabolic improvements, suggesting a potential association between pre-intervention microbiome composition and treatment response.
trial registrationThe Clinical Research Information Service of the Korea Center for Disease Control and Prevention, Number: KCT0010340.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.